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In cells infected with the Kaposi’s sarcoma-associated herpesvirus (KSHV), CSL/CBF1 signaling is essential
for viral replication and promotes the survival of KSHV-infected cells. CSL/CBF1 is a DNA adaptor molecule
which recruits coactivator and corepressor complexes to regulate viral and cellular gene transcription and
which is a major downstream effector molecule of activated Notch. The interaction of KSHV RTA and LANA
with CSL/CBF1 has been shown to balance the lytic and latent viral life cycle. Here we report that a third KSHV
protein, viral interferon regulatory factor 4 (vIRF4/K10), but none of the three other KSHV-encoded vIRFs,
interacts with CSL/CBF1. Two regions of vIRF4 with dissimilar affinities contribute to CSL/CBF1 binding.
Similar to Notch, vIRF4 targets the hydrophobic pocket in the beta trefoil domain of CSL/CBF1 through a
short peptide motif which closely resembles a motif found in Notch but does not strictly follow the WP
consensus conserved in human and mouse Notch proteins. Our results suggest that vIRF4 might compete with
Notch for CSL/CBF1 binding and signaling.
The Kaposi’s sarcoma-associated herpesvirus (KSHV) is the
etiological agent of infectious Kaposi’s sarcoma (KS) and is
also closely associated with the pathogenesis of primary effu-
sion lymphoma (PEL) and multicentric Castleman’s disease
(MCD). Like all herpesviruses, KSHV can switch between a
lytic and latent life cycle. In KSHV-infected cells, CSL/Notch
signaling has been shown to promote the survival of latently
infected cells and to control the balance between establishment
of latency and viral reactivation (12).
Notch receptors are transmembrane proteins. Upon ligand
binding, Notch receptors are proteolytically cleaved in a mul-
tistep process involving -secretase activity at one stage. The
intracellular Notch fragment (NICD) translocates into the cell
nucleus and binds to the CSL/CBF1 protein. CSL [CBF1/RBP-
J, Su(H), and Lag1] is a sequence-specific DNA binding fac-
tor which recruits corepressor and coactivator complexes to
cis-regulatory elements of its target genes. NICD is a transcrip-
tion factor which, in complex with MAM (Mastermind), acti-
vates transcription. NICD consists of an unstructured N-ter-
minal region called RAM (RBP-J-associated molecule),
followed by an Ankyrin (ANK) domain, a Q-rich region, and a
PEST-rich region (reviewed in reference 16).
The crystal structure of the DNA/CBF1 complex, as well as
that of the DNA/CBF1 complex associated with NICD frag-
ments, has been solved. The CBF1 protein consists of an N-
terminal domain (NTD), a modified -trefoil domain (BTD),
and a C-terminal domain (CTD). CBF1 binds DNA via ex-
tended regions in NTD and BTD. NICD interacts with two
regions of CBF1, BTD and CTD. Twenty-five N-terminal res-
idues of RAM bind with high affinity to a hydrophobic pocket
built by the BTD (17, 30, 39, 42). A WP motif within this
stretch of 25 amino acids, where  represents any hydrophobic
residue, is shared by all mouse and human Notch proteins, is
highly conserved across the orthologs of diverse species, and is
absolutely critical for the RAM/CBF1 interaction. In addition,
the ANK domain interacts with the CTD of CBF1. This inter-
action is weak and is stabilized by association with MAM
proteins (5, 33, 34).
Notch signaling is an evolutionary conserved signal trans-
duction pathway which regulates multiple developmental pro-
cesses, including stem cell renewal. Mammalian cells can ex-
press 4 Notch receptors. Dysregulated Notch signaling has
been directly linked to multiple human disorders, including
cancer (16). In KSHV-infected PEL B cells and KS cells of
endothelial origin, Notch signaling is active and contributes to
the cellular phenotype and survival in cell culture and in trans-
planted tumors in vivo (3, 4, 19, 22). KSHV infection can
modulate Notch signaling at multiple levels. Viral genes regu-
late the transcription of components of the Notch signaling
pathway or directly stabilize the intracellular Notch protein
and thereby enhance or prolong Notch signaling (7, 23, 29). In
addition, two viral proteins, RTA and LANA, have been
shown to directly bind to CBF1, the central downstream com-
ponent of Notch signaling. RTA (replication and transcription
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activator), the lytic switch protein, is a transactivator which
either directly contacts DNA or uses transcription factors as
adaptors to gain access to promoters. The interaction of RTA
and CBF1 controls the activation of multiple viral target genes
and is absolutely critical for virus reactivation (26–28, 38).
LANA, the latency-associated nuclear antigen, is a multifunc-
tional viral oncoprotein critical for the establishment of la-
tency. The interaction of LANA with CBF1 antagonizes RTA
functions and thereby stabilizes the status of latent infection in
the cell (20, 21).
Since CBF1 appears to be a signaling molecule controlling
cellular survival and the viral life cycle of KSHV-infected cells,
we examined whether further viral CBF1 interaction partners
could be identified. By means of a yeast two-hybrid screen, we
discovered viral interferon regulatory factor 4 (vIRF4/K10) as
a novel CBF1 interacting partner. The CBF1/vIRF4 interac-
tion shares several characteristic features with the CBF1/Notch
interaction. vIRF4 contacts CBF1 via two regions of differen-
tial affinity. The strong CBF1-interacting region of vIRF4 in-
cludes a peptide which closely resembles the conserved CBF1
binding motif described for NICD, which contacts BTD and
can abolish CBF1/NICD complex formation. Our data suggest
that vIRF4 is a potential antagonist of Notch/CBF1 signal
transduction.
MATERIALS AND METHODS
Plasmids. The Gateway-compatible destination vectors pGADT7, pHACR3,
and pMycCR3 (41), as well as pHACS1, pMycCs1, the NICD expression vector
(pED1), the CBF1 expression vector (AJ247), and the CBF1-dependent reporter
gene construct (pGA981-6), have been described previously (6, 31, 32). The open
reading frames of the EEF233AAA and KLV249AAA CBF1 mutants were
inserted into the XbaI/XhoI restriction sites of pHACS1, generating the plasmids
BS298 and BS299. F235I, K249M, and A258V (10) were inserted into the NotI/
XbaI sites of pHACS1, generating the plasmids pKF202, pKF203, and pKF204.
The designations of the amino acids throughout the manuscript refer to Gen-
Bank entry NM_005340 and Swiss-Prot entry Q06330. The vectors pGBKT7 and
pGADT7 (Clontech), pcDNA3.1-lacZ (Invitrogen), and pGEX-6-P1 (GE-
Healthcare) are commercially available. For bacterial expression of the His-
tagged BTD CBF1 fragment, the region coding for amino acids (aa) 158 to 323
of CBF1 was amplified by PCR using forward (fw) and reverse (re) primers (fw,
5 GGCGCCATGGAGAAGCAGTCATTGAAAAATGCTG; re, 5 AGTGGT
ACCTTATGCCTTATCTGTGCTAATGAT) which carry restriction sites for
NcoI or KpnI and ligated into the pETM11 vector, encoding an additional Z tag,
provided by Arie Gerlof.
For expression of the glutathione S-transferase (GST)-tagged RAM domain,
the region coding aa 1761 to 1890 of human Notch1 was amplified by PCR using
primers containing restriction sites for EcoRI and NotI (fw, 5 CGGAATTCA
TGCGGCGGCAGCATGGCC; re, 5 TTAGCGGCCGCTTTAGCAGGAGG
CGATCATGAG) and cloned into the vector pGEX-6-P1.
The pENTRY constructs encoding vIRF4, vIRF1, and vIRF3 have been pub-
lished (40). For construction of vIRF4 deletion mutants, the fragments were
amplified by PCR using the following forward and reverse primers: [KHe188.1],
aa 315 to 911 (fw, 5 GGAGATCTTCCTGTCACGG; re, 5 ATGTAGACTAT
CCCAAATG); [KHe192.1], aa 731 to 911 (fw, 5 CAGCGGGTGTCTTTTG
TTG; re, 5 ATGTAGACTATCCCAAATG); [KHe415], aa 1 to 314 (fw, 5
CCTAAAGCCGGTGGC; re, 5 CCATGGAAAACACGCAGG); [KHe416], aa
1 to 240 (fw, 5 CCTAAAGCCGGTGGC; re, 5 AGCAGGCGGATCTCCG);
[KHe417], aa 1 to 160 (fw, 5 CCTAAAGCCGGTGGC; re, 5 GTAGCTTTG
TTCTCTAGTG); [KHe370], aa 1 to 80 (fw, 5 CCTAAAGCCGGTGGC; re, 5
ACGTCCATACACCGTCTG); [KHe378], aa 161 to 240 (fw, 5 GAGGAGGC
AGGGGCTG; re, 5 AGCAGGCGGATCTCCG); [KHe461], aa 140 to 240 (fw,
5 CTGTTGTCCCCCCCAATG; re, 5 AGCAGGCGGATCTCCG); [KHe462],
aa 161 to 200 (fw, 5 GAGGAGGCAGGGGCTG; re, 5 GGCAGCCTTCTGT
TCAGTC); [KHe463], aa 201 to 240 (fw, 5 TGCTCCGTGTGGATACCAG; re,
5 AGCAGGCGGATCTCCG).
All forward and reverse primers were flanked by attB sites in the 5 flanking
region AAAAAGCAGGCTCCGCCATG (fw) or AGAAAGCTGGGTCTA
(re), respectively. The PCR products were cloned by BP clonase into pDONR207
(Invitrogen). The plasmid expressing [KHe142], aa 1 to 632, was created by
restriction digestion with NdeI/HindIII of pENTRY/vIRF4, Klenow treatment,
and subsequent blunt-end ligation.
For expression of the vIRF4 wild-type (wt) or deletion mutants, fragments
were transferred into the destination vector pHACR3, pMycCR3, or pGADT7
by LR reactions (Gateway; Invitrogen).
Point mutations and deletions in wild-type pENTRY/vIRF4 were generated by
using the Phusion site-directed mutagenesis kit from New England Biolabs with
the following forward and reverse primers: [KHe785.1], aa 1 to 911, W471A/
P473A (fw, 5 ACGCCGTGGTGCCGGAAGTTCGCAC; re, 5 GACCAACT
GGGGCGTGGGCAACAGGCGCG), and [KHe815], aa 1 to 911, 201-240
(fw, 5 CCATCAACGCTGACCGGCCCTTCAG; re, 5 GGCAGCCTTCTGT
TCAGTCGTTATATCGC).
vIRF4/K10 expression constructs were generated by hybridizing complemen-
tary single-stranded oligonucleotides encoding short stretches of open reading
frames flanked by EcoRI/XhoI restriction sites and ligated into the correspond-
ing sites of the vectors pHACR3 and pGADT7. The following oligonucleotides
were used: [KHe568.1], aa 201 to 220 (fw, 5 GATCGAATTCTGCTCCGTGT
GGATACCAGTGAATGAGGGCGCATCTACCTCAGGTATGGGGTCCTC
TGGGTGACTCGAGGATC; re, 5 GATCCTCGAGTCACCCAGAGGACCC
CATACCTGAGGTAGATGCGCCCTCATTCACTGGTATCCACACGGAG
CAGAATTCGATC); [KHe568.2], aa 221 to 240 (fw, 5 GATCGAATTCACG
CGACAAGTTACGCAGGCCTCGTCCTTTACGTGGCGGGTTCCCGGAG
ATCCGCCTGCTTGACTCGAGGATC; re, 5 GATCCTCGAGTCAAGCAG
GCGGATCTCCGGGAACCCGCCACGTAAAGGACGAGGCCTGCGTAA
CTTGTCGCGTGAATTCGATC); [KHe812], aa 466 to 478, W471A/P473A
(fw, 5 GATCGAATTCGCAATACGCGCGCCTGTTGCCCACGCCCCAGT
TGGTCACGCCGGATGACTCGAGGATC; re, 5 GATCCTCGAGTCATCC
GGCGTGACCAACTGGGGCGTGGGCAACAGGCGCGCGTATTGCGA
ATTCGATC); and [KHe184], aa 466 to 478 (fw, 5 GATCGAATTCGCAATA
CGCGCGCCTGTTTGGCACCCACCAGTTGGTCACGCCGGATGACTCG
AGGATC; re, 5 GATCCTCGAGTCATCCGGCGTGACCAACTGGTGGGT
GCCAAACAGGCGCGCGTATTGCGAATTCGATC).
For construction of pENTRY/vIRF2 [KHe486], total RNA from 12-O-tetra-
decanoylphorbol-13-acetate (TPA)-induced BCBL-1 cells was isolated and re-
verse transcribed, and a first-round PCR was done with the gene-specific forward
(5AGCTAGTTGTGGCGAGAAAG) and reverse (5CCCACATGGGCCTAC
TATAAC) primers. This PCR was followed by a second-round PCR using
forward (5AAAAAGCAGGCTCCGCCATGCCTCGCTACACGGAG) and
reverse (5AGAAAGCTGGGTCTATTAGTCTCTGTGGTAAAATGG) prim-
ers which added attB sites.
Expression of proteins in bacteria and in vitro. The recombinant His-tagged
full-length CBF1 protein has been described previously (31). The expression
vectors for His fusion proteins were transformed into BL21(DE3)pLysS (Pro-
mega) Escherichia coli, and bacteria were grown at 37°C until a cell optical
density at 600 nm (OD600) of 0.6 was reached. The culture was then induced with
0.5 mM isopropyl--D-thiogalactopyranoside (IPTG), grown for 2 h at 30°C,
harvested by centrifugation, and frozen. Frozen bacterial pellets were resus-
pended in buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1 M urea, and
protease inhibitors (Roche) and lysed by sonication. The resulting lysate was
clarified by centrifugation (15,000  g), loaded onto Perfecto Pro nickel-nitrilo-
triacetic acid agarose (5Prime), preequilibrated with buffer, and then applied to
chromatography columns (Bio-Rad). The column was washed with 10 to 20
volumes of the buffer, and the protein was eluted by buffer with 50 mM reduced
glutathione. Glutathione and urea were removed by dialysis against buffer con-
taining 50 mM Tris (pH 8.0), 150 mM NaCl, 2 mM dithiothreitol (DTT), and 10
mM EDTA.
The expression vector for GST fusion proteins was transformed into
Rosetta(DE3)pLysS (Novagen) E. coli, and bacteria were grown in LB medium
at 37°C until a cell OD600 of 0.8 was reached. The culture was then induced with
1 mM IPTG, grown for 4 h at 30°C, and harvested by centrifugation, and cell
pellets were frozen. Frozen bacterial pellets were resuspended in buffer contain-
ing 50 mM Tris (pH 8.0), 150 mM NaCl, 1 M urea, and complete protease
inhibitors (Roche) and lysed by sonication. The resulting lysate was clarified by
centrifugation (15,000  g), loaded onto glutathione Sepharose 4B beads (GE
health care), preequilibrated with buffer, and then applied to chromatography
columns (Bio-Rad). The column was washed with 10 to 20 volumes of the buffer,
and the protein was eluted with 250 mM Imidazole in lysis buffer. Imidazole and
urea were removed by dialysis against buffer containing 50 mM Tris (pH 8.0), 150
mM NaCl, 2 mM DTT, and 10 mM EDTA.
In vitro-translated proteins were produced using T7-coupled reticulocyte ly-
sates (Promega).
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Peptide synthesis. The solid-phase synthesis of the peptides, including the
peptides for the plaque reduction assay, was carried out on a Pioneer automatic
peptide synthesizer (Applied Biosystems, Foster City, CA) employing Fmoc
chemistry with O-benzyltriazol-1-yl)-N,N,N,N-tetramethyluronium tetraflu-
oroborate (TBTU)/diisopropylethyl amine activation. Side chain protections
were as follows: Asp, Glu, Ser, Thr, and Tyr, t-Bu; Asn, Gln, and His, Trt; Arg,
Pbf; Lys and Trp, Boc. Coupling time was 1 h. Double couplings were carried out
if a difficult coupling was expected according to the program Peptide Companion
(CoshiSoft/PeptiSearch, Tucson, AZ). All peptides were generated as carboxyl
amides by synthesis on Rapp S RAM resin (Rapp Polymere, Tu¨bingen, Ger-
many). Biotin was incorporated at the C termini of indicated peptides with
Fmoc-Lys(biotin)-OH (NovaBiochem/Merck, Nottingham, United Kingdom)
and TBTU/diisopropylethyl amine activation for 18 h, followed by coupling of
Fmoc--Ala-OH for 1 h. Peptides were cleaved from the resin and deprotected
by a 3 h of treatment with trifluoroacetic acid (TFA) containing 3% triisobutyl-
silane and 2% water (10 ml/g resin). After precipitation with t-butylmethyl ether,
the resulting crude peptides were purified by preparative high-pressure liquid
chromatography (HPLC) (RP-18) with water-acetonitrile gradients containing
0.1% TFA and characterized by analytical HPLC. Sequences of the peptides
were as follows: Notch, biotin--Ala--Ala-RRQHGQLWFPEGF-amide (wt)
and biotin--Ala--Ala-RRQHGQLLAAEGF-amide (mutant [mt]); EBNA-2,
biotin--Ala--Ala-HHLPSGPPWWPPV-amide (wt) and biotin--Ala--Ala-
HHLPSGPPSRPPV-amide (mt); vIRF4, biotin--Ala--Ala-IRAPVWHP
PVGHAVV-amide (wt) and biotin--Ala--Ala-IAAPVAHAPVGHA-amide.
Yeast two-hybrid screen. The ORFeome library for KSHV and the screening
procedure have been described previously (40). Yeast strains AH109 and Y187
were transformed with either the ORFeome library inserted into the vector
pGADT7 DEST or CBF1 inserted into pGBKT7, respectively. Y187 trans-
formed with pGBKT7 without an insert was processed in parallel. Yeast strains
were cultured, transformed, and assayed for two-hybrid interactions according to
the protocols provided by Invitrogen.
Yeast two-hybrid assay. Yeast strain AH109 was transformed with 1 g of
either vIRF4 or vIRF4 mutants inserted in the Gal4 activation domain (AD)
vector (pGADT7) together with 1 g of CBF1 inserted in the Gal4 DNA binding
domain vector (DBD) (pGBKT7). Cotransformations were also done with vec-
tors containing no insert. Yeast cells were transformed using polyethylene glycol
(PEG)/lithium acetate (LiAc) solution (40% PEG, 100 mM LiAc, 10 mM Tris,
1 mM EDTA, pH 7.5) together with salmon testes DNA. Transformed cells were
plated onto synthetic complete medium lacking leucine and tryptophan. Repre-
sentative colonies were replica plated onto medium lacking leucine, tryptophan,
and adenine or histidine in the presence of different concentrations of 3-amino-
triazole (3-AT).
Cell lines, culture conditions, and induction of the lytic cycle. The cell lines
BC-1 (2), BCBL-1 (35), HEK293 (11), and DG75 knockout (KO) (SM224.9) (31)
have been described previously.
Cell lines were grown in 1640 RPMI supplemented with 10% fetal calf serum,
100 U penicillin per ml, 100 g streptomycin per ml, and 4 mM glutamine and
maintained at 37°C in a 5% CO2 atmosphere. BC-1 and BCBL-1 were supple-
mented with 20% fetal calf serum. For lytic cycle activation, cells were treated
with 3 mM sodium butyrate (NaB) and/or 20 ng/ml TPA as appropriate.
Transfection of cells. On the day of transfection, medium of HEK293 cells,
plated on 10-cm dishes, was replaced by Optimem. Cells were transfected with 5
g of each plasmid and 12 g polyethylenimine (Sigma) in the presence of
Optimem. After 4 h, the medium was replaced with RPMI 1640 cell culture
medium containing 10% fetal bovine serum, and cells were further cultured for
24 h before harvesting. DG75 wild-type or KO (SM224.9) cells (1  107) were
resuspended in 250 l RPMI 1640 and transfected with 5 g of each plasmid
DNA by electroporation (220 V, 950 F) using a Gene Pulser II system (Bio-
Rad). Cells were harvested 48 h after transfection.
Antibodies. The CBF1-specific rat monoclonal antibody RBJ-7A11 has been
described previously (31). In order to produce rat monoclonal antibodies, a
vIRF4 fragment consisting of the first 313 amino acids was expressed as a
GST-tagged fusion protein, purified by glutathione Sepharose affinity chroma-
tography, and used to immunize rats as described previously (18). The entire
open reading frame of CBF1 was expressed as a His-GST tandem-tagged fusion
protein and purified by Ni chelate affinity. The vIRF4-specific antibody vIRF-8F8
was used for immunoprecipitation and immunoblotting. The CBF1-specific an-
tibody RBJ-6E7 was used for immunoprecipitation, the antibody RBP-7A11 was
used for immunoblotting, and the antibody RBJ-1F1 was used for supershift
experiments in electrophoretic mobility shift assays (EMSAs). The rat hemag-
glutinin (HA)-tag-specific antibody was purchased from Roche. The mouse Myc-
tag-specific antibody was 9E10-derived supernatant. The His-specific mouse an-
tibody was N-His 2F12 supernatant (E. Kremmer, unpublished).
Immunoprecipitation and immunoblotting. Cells were lysed in NP-40 lysis
buffer (1% NP-40, 140 mM NaCl, 5 mM MgCl2, 20 mM Tris, pH 7.6) supple-
mented with complete protease inhibitor cocktail (Roche) and sonicated. Total
cell extracts were directly loaded onto the gel for immunoblotting or used for
coimmunoprecipitation by adding 100 l of hybridoma supernatant or 1 g of
purified antibody for 1 h on ice, followed by protein G-coupled Sepharose beads
and incubation overnight. Immunoprecipitates were washed 3 times with NP-40
lysis buffer, Laemmli buffer was added to the beads, and the samples were boiled,
submitted to electrophoresis by SDS-PAGE, and analyzed by immunoblotting on
polyvinylidene difluoride (PVDF) membranes; proteins were detected by specific
antibodies and the chemiluminescence system (Amersham Biosciences) accord-
ing to the manufacturer’s instructions.
Affinity precipitation of protein complexes by biotinylated oligonucleotides.
Five hundred micrograms cell extract of TPA and NaB-treated or untreated
BC-1 cells was incubated for 10 min at 4°C with binding buffer (10 mM Tris-HCl,
pH 8, 40 mM KCl, 1 mM dithiothreitol [DTT], 6% glycerol, 0.05% NP-40) and
20 l of poly(dIdC) in a final volume of 1 ml. One g of a biotin-labeled
oligonucleotide carrying the CBF1 recognition motif of the Epstein-Barr virus
(EBV) C-promoter (fw, 5 AAGTTGGTGTAAACACGCCGTGGGAAAAAA
TTTATGGTT, re, 5 GAACCATAAATTTTTTCCCACGGCGTGTTTACAC
CAACTT) was added and incubated for 4 h at 4°C. As a control, we used a
nucleotide sequence carrying the C/EBP binding site (fw, 5 TTATGTTAAGA
ATTTGTGCAAGTCTACCGTATT; re, 5 AATACGGTAGACTTGCACAA
ATTCTTAACATAA).
Then, 50 l of a 50% slurry of streptavidin-coated agarose beads (Invitrogen)
was added, followed by 2 h of incubation at 4°C. Beads containing bound
complexes were washed twice with Tris-EDTA (100 mM NaCl) and twice with
binding buffer before adding Laemmli buffer. Samples were submitted to elec-
trophoresis by SDS-PAGE and analyzed by immunoblotting.
Hybridization of peptide arrays with radiolabeled probes. Peptides represent-
ing the entire open reading frame of vIRF4 as overlapping 15-mers were syn-
thesized on a cellulose membrane as described previously (1). Nine g plasmid
DNA encoding CBF1 in pMycCS1 was in vitro transcribed and translated in the
presence of [35S]methionine using the TNT-T7-coupled reticulocyte lysate (Pro-
mega). Membranes were activated with 100% ethanol, washed with TBS (138
mM NaCl, 2.7 mM KCl, 50 mM Tris base), blocked in blocking buffer (5 M NaCl,
1 M Tris base, pH 6.8, 2.5% skim milk powder, 0.05% Tween 20) overnight, and
saturated with 100 mM cysteine in blocking buffer for 30 min. Membranes were
incubated with the radiolabeled CBF1 probe in blocking buffer for 3 h. Mem-
branes were washed for three times with TBS-T (TBS plus 0.05% Tween 20).
Signals indicating protein binding were quantified on a phosporimager using the
AIDA software program. The results are given as arbitrary units.
Reporter gene assays. Transfections were done in triplicate, and 1  107 cells
were transfected with a mixture of 5 g luciferase reporter plasmid pGa981-6, 1
g pcDNA3.1-lacZ, and 5 g of each expression plasmid. The DNA amounts
were adjusted by adding the corresponding empty vector. Cells were harvested
48 h after transfection, washed with phosphate-buffered saline (PBS), lysed in
100 l LUC extraction buffer (10% [wt/vol] glycerin, 1% [wt/vol]) Triton X-100,
2 mM EDTA, 25 mM Tris-HCl, pH 7.8, 2 mM DTT). Cell debris was removed
by centrifugation at 4°C and 16,000  g for 15 min. Luciferase activity was
determined using 10 l of the clarified lysates in duplicate, followed by injection
of 50 l luciferase assay buffer [20 mM Tricine, 1.07 mM 4MgCO3  Mg(OH)2 
5H2O), 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 M coenzyme A,
470 M luciferin, 530 mM ATP]. Luciferase activity was normalized for varia-
tions in transfection efficiencies by cotransfection of the cytomegalovirus (CMV)
-galactosidase (-Gal) reporter plasmid (pcDNA3.1-lacZ). For the -galacto-
sidase assay, 10 l of the lysates in duplicates were incubated for 20 min at room
temperature with 100 l -Gal assay buffer (100 mM Na-P, pH 8.0, 1% Galacton
[Tropix, Bedford, MA], 1 mM MgCl2). The reaction was started by adding 50 l
of -Gal acceleration buffer (0.2 M NaOH, 10% Emerald enhancer) and mea-
sured in a luminometer (LB9501; Berthold).
EMSA. The oligonucleotide Cp (SM316Cs, 5-AAGTTGGTGTAAACACGC
CGTGGGAAAAAA-3; SM316Cas, 5-GAACCATAAATTTTTTCCCACGG-
3) was annealed by mixing of equimolar ratios of sense and antisense oligonu-
cleotides in annealing buffer (10 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 50 mM
NaCl), incubation at 90°C for 10 min, and cooling down to 37°C. Twenty-five ng
of the annealed oligonucleotides were blunt ended by Klenow polymerase in the
presence of lsqb]	-32P]dCTP (3,000 Ci/mmol) and unlabeled dATP, dGTP, and
dTTP at 37°C for 1 h. The labeled probe was separated from unincorporated
nucleotides using Nick Sephadex G50 columns (Amersham Biosciences). A 0.5-
to 1-ng amount of 32P-labeled oligonucleotide probe was incubated in a 20-l
reaction mixture containing 10 mM HEPES (pH 7.9), 1 mM EDTA, 200 mM
KCl, 4% Ficoll, 2 g bovine serum albumin (BSA), 2 g poly(dI-dC), 4 mM
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DTT, and proteinase inhibitors, with or without competitive unlabeled oligonu-
cleotide, and 5 pmol recombinant purified CBF1 protein or 40 pmol RAM
protein protein-DNA complexes were resolved on 6% polyacrylamide gels in 1
Tris-borate-EDTA (TBE) buffer at room temperature for 3 h at 130 V. Gels
were dried and exposed to X-ray films or Fujifilm imaging plates. After the
Fujifilm imaging plates were scanned with the phosphorimager Fujifilm FLA-
5100, the quantification of EMSA gels was performed using AIDA image ana-
lyzer software.
Peptide affinity precipitation. Peptides were dissolved in PBS at a concentra-
tion of 5 mM. Streptavidin beads (Invitrogen) were washed with PBS–0.1%
Triton X. Streptavidin beads were coated with 50 nM peptide per 1 ml beads for
3 h at 4°C, washed with PBS–0.1% Triton X, and subsequently dissolved as 50%
slurry. For affinity precipitation, 500 pM of BTD-CBF1 was incubated with 40 l
streptavidin beads and preequilibrated with pulldown buffer containing 150 mM
KCl, 20 mM HEPES, pH 7.9, 0.2 mM EDTA, 0.2% Triton X, and 25% (vol/vol)
glycerol in a volume of 1 ml for 3 h at 4°C. Precipitates were washed with
pulldown buffer, Laemmli buffer was added to the beads, and the samples were
boiled, submitted to electrophoresis by SDS-PAGE, and analyzed by immuno-
blotting on PVDF membranes, and proteins were detected by specific antibodies
with the chemiluminescence system (Amersham Biosciences) according to the
manufacturer’s instructions.
RESULTS
vIRF4 is a novel viral CBF1 binding partner. In order to
screen for additional KSHV proteins, which bind to CBF1, we
carried out a yeast two-hybrid screen using an ORFeome li-
brary of KSHV fused to the GAL4 activation domain (40, 8).
The CBF1 sequence was fused to the GAL4 DNA binding
domain and used as bait. Out of a group of several candidates,
vIRF4 was consistently identified in different independent ex-
periments (data not shown). To verify that this interaction can
also be found in KSHV-infected cells, we performed coimmu-
noprecipitations using EBV plus KSHV-positive BC-1 cells
and KSHV-positive BCBL-1 cells. Since vIRF4 is known to be
expressed with early kinetics after reactivation of the virus,
BC-1 and BCBL-1 cells were treated with sodium butyrate
(NaB) and/or 12-O-tetradecanoylphorbol-13-acetate (TPA),
and the cell lysates were examined for complex formation (Fig.
1A and B). Indeed, CBF1 coprecipitated with vIRF4-specific
antibodies in lysates derived from both cell lines. The vIRF4
precipitates and CBF1 coprecipitates detected in untreated
BCBL-1 cells are likely to be derived from spontaneously re-
activating cells frequently seen in this cell line. We thus con-
firmed that vIRF4 is a novel viral interaction partner of CBF1
in KSHV-infected cells. Although the yeast two-hybrid system
typically identifies binary interactions not mediated by addi-
tional bridging proteins, we next wished to confirm that the
interaction can be formed by in vitro-translated proteins gen-
erated in reticulocyte lysates which are most likely devoid of
FIG. 1. CBF1 interacts directly and specifically with vIRF4. BC-1 (A) or BCBL-1 (B) cells (2  107) were treated with TPA or TPA plus NaB
for 48 h to induce the lytic cycle or were left untreated. Total cellular protein extracts were used for immunoprecipitation (IP) and immunoblotting
(IB) using the vIRF4-specific rat monoclonal antibody vIRF-8F8 or CBF1-specific rat monoclonal antibody RBJ-6E7 for IP and RBP-7A11 for IB.
The protein amount loaded onto the lysate lanes corresponds to 2% of cell extracts analyzed by immunoprecipitation. (C) In vitro-translated vIRF4
and HA-CBF1 were submitted to immunoprecipitation and immunoblotting using antibodies specific for vIRF4 and HA. (D) HA-tagged vIRF1,
vIRF2, vIRF3, and vIRF4 plus Myc-tagged CBF1 were coexpressed in HEK 293 cells by transfection of 5 g of each expression construct.
pMycCR3 and pHACR3 are the corresponding expression vectors carrying no insert. Complex formation was tested by coimmunoprecipitation
using the Myc-specific antibody and immunoblotting by CBF1- and HA-specific antibodies. The amount of protein lysate (L) corresponds to 2%
of the protein amount of the sample used for immunoprecipitation (IP).
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any bridging factors critical for complex formation (Fig. 1C). In
vitro translation products of both interaction partners, vIRF4
and HA-tagged CBF1, were examined for complex formation
by coprecipitation. The CBF1 coprecipitation by the vIRF4-
specific antibody was confirmed and shown to be strictly de-
pendent on vIRF4 in the sample, thereby excluding a potential
cross-reactivity of the vIRF4-specific antibody to CBF1.
We next wished to test whether, in addition to vIRF4, other
viral IRFs interact with CBF1. We therefore coexpressed HA-
tagged vIRF1/K9, vIRF2/K11, vIRF3/K10.5, or vIRF4/K10 in
HEK293 cells and tested for complex formation with CBF1 by
immunoprecipitation. While vIRF4 readily coprecipitated with
CBF1, none of the other vIRFs could do so (Fig. 1D). Thus,
vIRF4 appears to be the only vIRF interacting with CBF1.
Since CBF1 is a DNA anchor protein, which can recruit further
proteins to DNA, we tested whether vIRF4/CBF1 binding is com-
patible with CBF1/DNA complex formation by DNA affinity pu-
rification of vIRF4/DNA complexes. Our results showed that
biotinylated oligonucleotides carrying the CBF1 binding site of
the EBV C promoter (Cp) efficiently precipitated CBF1 and
coprecipitated vIRF4 from BC-1 lysates induced for viral reacti-
vation while an oligonucleotide carrying a C/EBP recognition site
was used as a control (Fig. 2A).
Since CBF1 is a central downstream component of Notch
signaling, we tested if vIRF4 has the potential to interfere with
Notch signal transduction. Taking advantage of the fact that
the intracellular Notch fragment (NICD) can be used to mimic
constitutively active Notch receptors, a CBF1-dependent re-
porter construct was coexpressed with vIRF4, NICD, or both
proteins. While NICD activated the CBF1-dependent reporter
gene, vIRF4 did not significantly modulate reporter gene ex-
pression. However, coexpression of NICD and vIRF4 but not
vIRF2 significantly diminished reporter gene activity, indicat-
ing that vIRF4 might potentially interfere with Notch signaling
(Fig. 2B). We thus speculated that vIRF4 might bind to CBF1
regions which are also targeted by Notch.
Two regions of vIRF4 contribute to CBF1 binding. In order
to map the CBF1 binding regions of vIRF4, two experimental
approaches, yeast two-hybrid binding assays and hybridization
of peptide arrays, were followed in parallel (Fig. 3).
For the yeast two-hybrid approach, a series of deletion con-
structs of vIRF4 encompassing N-terminal, C-terminal, and
internal vIRF4 fragments was generated. These vIRF4 frag-
ments were coexpressed in the yeast strain AH109 as GAL4
activation domain (AD) fusions together with CBF1 fused to
the GAL4 DNA binding domain (DBD). These transformants
and the respective controls were plated on permissive plates
lacking leucine and tryptophan. Through replica plating, they
were transferred to selective plates lacking adenine or histidine
and supplemented with increasing amounts of 3-aminotriazole
(3-AT). Interactions were scored as positive if they promoted
colony growth on adenine-free plates and on histidine-free
plates supplemented with at least 1 mM 3-AT (Fig. 3A). This
analysis revealed that a fragment within the N terminus of
vIRF4 consisting of aa 201 to 240 was sufficient to mediate
weak CBF1 binding (Fig. 3C). In addition, a C-terminal frag-
ment (aa 314 to 911) also promoted growth of CBF1-cotrans-
formed colonies (data not shown). In order to map this sec-
ondary binding region further, an array of overlapping peptide
fragments (15-mer peptides overlapping by 12 amino acids)
encompassing the entire open reading frame of vIRF4 was
synthesized on a cellulose membrane by SPOT synthesis (9)
and probed with in vitro-translated 35S-labeled CBF1. The re-
sulting signals were quantified by phosphorimaging (Fig. 3B).
Strong signals were obtained for peptides no. 154 to 156, which
share the 13-amino-acid sequence IRAPVWHPPVGHA, cor-
responding to aa 466 to 478 of vIRF4. Surprisingly, the region
aa 201 to 240, which had shown weak interactions in the yeast
FIG. 2. vIRF4 can bind to CBF1/DNA complexes and interfere with Notch driven reporter gene activation. (A) BC-1 cells were treated with
TPA and NaB for 24 h or left untreated. Protein extracts were harvested and a biotin labeled oligonucleotide derived from the EBV C-promoter
carrying the CBF1 recognition motif was added. In order to control for a potential unspecific binding of vIRF4 to DNA a biotin labeled
oligonucleotide carrying a C/EBP recognition site was analyzed in parallel. DNA-protein complexes were precipitated using streptavidin-coupled
beads. CBF1 and vIRF4 were visualized by immunoblotting using the monoclonal antibodies (RBP-7A11) and (vIRF-8F8), respectively. (B) HEK
293 cells were cotransfected with 500 ng Notch fragment NICD expression constructs or control vectors (pHACS1) and a CBF1-dependent
luciferase reporter gene (pGa981-6). Two hundred fifty or 500 ng of the HA-tagged vIRF4 or vIRF2 expression constructs were cotransfected when
indicated. The results represent triplicates and are shown as relative transactivation compared to Notch transactivation, which is set to 100%.
Standard deviations are shown as error bars. All results were normalized for -galactosidase activity derived from the reporter construct
pcDNA3.1-LacZ, included in each sample.
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two-hybrid system, did not score on the peptide array. Both
regions were reexamined in yeast two-hybrid experiments (Fig.
3C). Region aa 466 to 478 coexpressed with CBF1 permitted
yeast growth in histidine-free medium supplemented with up
to 35 mM 3-AT and thus scored as strong as the complete open
reading frame of vIRF4. In contrast, aa 201 to 240 could
support yeast growth only in medium containing 2.5 mM 3-AT.
Subfragments of aa 201 to 240 did not allow yeast growth. In
summary, aa 466 to 478 appears to be a strong CBF1-interact-
ing region, while aa 201 to 240 is sufficient to bind to CBF1
weakly and might have an auxiliary function.
Next, we examined the molecular details of the interaction
of aa 466 to 478 with CBF1. A library of mutant peptides
replacing each single amino acid of the 13-residue peptide (aa
466 to 478) with an alanine was synthesized, arrayed on filter
paper, and tested for interaction with 35S-labeled in vitro-trans-
lated CBF1. Alanine substitutions for tryptophan 471 (W471A)
or proline (P473A) resulted in a significant loss of binding
affinities (data not shown). A 13-residue peptide as depicted in
Fig. 4A, carrying both substitutions (aa 466 to 478, W471A/
P473A), was tested in yeast two-hybrid assays, and the loss of
CBF1 binding was confirmed (Fig. 4B, row 4).
In order to test if the two binding regions are indeed relevant
in the context of the complete open reading frame, a series of
vIRF4 mutants was generated which carried either a deletion
in position aa 201 to 240 (1-911201-240), the alanine replace-
ment mutations (1-911W471A/P473A), or both mutations (1-
911201-240/W471A/P473A). The CBF1 binding capacities of these
mutants were tested in parallel in yeast two-hybrid assays and
by coprecipitation in HEK293 cells (Fig. 4B and C). CBF1
binding of 1-911201-240 was not severely impaired according to
the yeast two-hybrid assay or coprecipitation experiments. In con-
trast, neither 1-911W471A/P473A nor 1-911201-240/W471A/P473A co-
precipitated CBF1 (Fig. 4B).
According to the yeast two-hybrid experiments, mutant
1-911W471A/P473A still retained a residual CBF1 binding activ-
FIG. 3. CBF1 interacts with two regions of vIRF4. (A) Schematic overview on results obtained with yeast. A series of vIRF4 deletion constructs
was generated, and the truncated protein was coexpressed as a GAL4 activation domain (AD) fusion with CBF1 GAL4 DNA binding domain
fusion proteins (DBD) in the yeast strain AH109. Transformants were plated on semisolid synthetic medium lacking leucine and tryptophan.
Representative colonies on these permissive plates were replica plated onto selective medium lacking histidine and supplemented with 2.5 mM
3-AT or lacking adenine and scored for growth. (B) Peptides representing the entire open reading frame of vIRF4 were synthesized and spotted
onto membranes. The peptides were 15 amino acids in length and overlapped by 12 amino acids. CBF1 was in vitro transcribed and translated in
the presence of [35S]methionine. The translation product was used as a probe. Signals indicating protein binding were quantified on a phospo-
rimager using the AIDA software program, and the results are given as arbitrary units. The region corresponding to aa 466 to 478 (peptides 154
to 156) gave the best signals. Surprisingly, a second region, corresponding to aa 201 to 240 (peptides 64 to 80), which had scored for binding in
the yeast two-hybrid experiment, did not score in this assay. (C) Two representative colonies of all transformants expressing the indicated vIRF4
fragments were grown on permissive synthetic medium and then replica plated onto selective plates lacking histidine supplemented with increasing
amounts of 3-AT or lacking adenine and tested for interaction. pGADT7 and pGBKT7 are the yeast expression vectors carrying no insert.
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ity, since yeast transformants grew in the presence of 10 mM
3-AT, as opposed to wild-type transformants, which grew on
medium supplemented with 25 mM 3-AT (Fig. 4C). In con-
trast, 1-911201-240/W471A/P471A yeast transformants did not
grow on histidine-free medium supplemented with more than
1 mM 3-AT or on medium lacking adenine, indicating that aa
201 to 240 can contribute to the avidity of the vIRF4/CBF1
interaction. In summary, our data suggest that vIRF4 and
CBF1 associate by a binary interaction but the WXP motif
provides the dominant binding site.
vIRF4 contacts regions of CBF1 which are also critical for
Notch binding. Interestingly, the sequence of the 13-residue
vIRF4 peptide which appears to constitute the high-affinity
binding site for CBF1 closely resembles peptides within the
Notch RAM domain and the EBNA-2 conserved region 6
which are critical for CBF1 binding (Fig. 4A). Both peptides
carry critical W and P residues in close proximity. However, the
vIRF4 peptide (IRAPVWHPVGHA) does not perfectly match
the consensus motif WP of the Notch and EBNA-2, since
the position of the second hydrophobic residue is occupied by
a positively charged histidine. The WP motifs of both
Notch and EBNA-2 interact with a hydrophobic pocket on the
surface of CBF1-BTD. To test whether the vIRF4 peptide also
contacts the BTD, BTD (CBF1 fragment aa 158 to 323) was
heterologously expressed in bacteria, and biotinylated vIRF4,
Notch, or EBNA-2 peptides were used to affinity precipitate
the BTD fragment of the CBF1 protein (Fig. 5A). These ex-
periments demonstrated that all peptides which carry the con-
served WXP residues readily precipitated the BTD while mu-
tants with substitution of W and/or P were inactive.
Mutations located within the loop of the BTD or the hydro-
phobic pocket have been previously described to abolish the
CBF1-Notch interaction (7, 11). These mutants include the
CBF EEF233AAA, KLV249AAA, F235I, K249M, and A258V
mutants (Fig. 5B). If vIRF4 and Notch target similar residues
of CBF1, we expected that these loss-of-function mutants
should be impaired for interaction with vIRF4 as well. We first
confirmed the phenotype of the mutants we wanted to use.
Since NICD/CBF1 coprecipitations work poorly in our hands,
we performed luciferase assays using a CBF1-dependent re-
porter gene system. We have recently generated a CBF1-neg-
ative human DG75 B cell line by homologous recombination.
NICD and CBF1 or CBF1 mutants were coexpressed in CBF1-
negative DG75 cells. As expected, wild-type CBF1 reconsti-
tuted promoter activation, EEF233AAA and KLV249AAA
mutants were strongly impaired in supporting reporter gene
activation, and mutants carrying single amino acid substitu-
tions were significantly impaired (Fig. 5C). Formation of co-
precipitates was tested by coexpression of vIRF4 and the re-
spective HA-tagged CBF1 mutants in HEK293 cells using an
HA-specific antibody and immunoblotting (Fig. 5D). Indeed,
both triple amino acid mutants, carrying EEF233AAA and
KLV249AAA, known to abolish NICD binding, could not pre-
cipitate vIRF4, while wild-type CBF1 readily did so. The sin-
gle-amino-acid substitution K249M and A258V mutants did
not bind to vIRF4 either, while the F235I mutant retained
FIG. 4. The high-affinity CBF1 binding motif in vIRF4 closely resembles the motif found in the Notch-RAM domain. (A) Schematic drawing
of the vIRF4 regions targeted by mutagenesis. (B) HEK 293 cells were transfected with 10 g expression plasmids encoding HA-vIRF4 and the
respective HA-tagged mutants. CBF1 binding was tested by immunoprecipitation using HA-specific antibodies and immunoblotting by CBF1-
specific antibody (RBP-7A11) or immunoprecipitation using the CBF1-specific RBJ-6E7 antibody and the HA-specific antibody for immunoblot-
ting. Isotype controls, matching the HA-specific and RBJ-6E7 antibody, were performed in parallel. (C) AH209 yeast cells cotransformed with
vectors expressing AD-vIRF4 or AD-vIRF4 mutants and DBD-CBF1 or the respective control vectors were tested for growth on selective medium
supplemented with increasing amounts of 3-AT.
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residual vIRF4 binding activity. In summary, these results in-
dicated that vIRF4 binds to CBF1 via the hydrophobic pocket
in BTD and thus might compete for NICD/CBF1 complex
formation.
In order to directly prove that the vIRF4 peptide can interfere
with NICD/CBF1 complex formation on DNA, we performed gel
retardation experiments using bacterially expressed binding part-
ners (Fig. 6). CBF1 and RAM complex formation on radiolabeled
Cp oligonucleotides was tested in the presence of Notch- or
vIRF4-derived peptides and mutant controls, which had also been
used for affinity studies. All peptides efficiently and specifically
abolished complex formation, confirming that the biological ac-
tivities of all peptides are equivalent and histidine is tolerated in
the position occupied by a nonpolar residue in the consensus
sequence of most Notch proteins.
DISCUSSION
In this study, we describe the interaction of CBF1 with the
early lytic vIRF4 protein. KSHV encodes a cluster of genes
designated vIRFs since their open reading frames all share
limited sequence homology with cellular IRFs (36). vIRF1, -2,
and -3 have been shown to modulate interferon (IFN) induc-
tion and responsiveness and p53 and NF-B activity (24).
vIRF4 localizes predominantly to the nucleus in KS and PEL
but can also be found in the cytoplasm cells in of MCD samples
(15). Similarly, transient transfection of vIRF4 expression con-
structs into HEK293 cells generally results in a nuclear staining
pattern. Interestingly, vIRF4 can interact with at least 15
KSHV proteins (40), and coexpression of vIRF4 with viral
binding partners can influence its subcellular localization, re-
FIG. 5. vIRF4 and the Notch Ram domain target similar sites in CBF1. (A) The BTD of His-CBF1 (aa 158 to 323) was expressed in bacteria,
and the purified protein was incubated with biotinylated peptides derived from vIRF4/K10, human Notch1, or EBNA-2. The conserved W and P
residues were replaced in mutant peptides. Peptide/CBF1 complexes were affinity precipitated on streptavidin beads, and CBF1 was detected using
a His-specific antibody in Western blots. (B) Illustration of the localization of the 3 mutations inserted into the CBF1 protein. (C) CBF1-negative
DG75 cells (SM224.9) were transfected with 5 g of expression plasmids for NICD and CBF1 (wt) or the respective CBF1 mutants and 3 g
CBF1-dependent luciferase reporter gene construct (pGa981-6). Results are shown as the means and standard deviations of triplicate experiments
as relative luciferase units (RLU) normalized for -galactosidase activity derived from the reporter construct (pcDNA3.1-lacZ) included in each
sample. (D) HEK 293 cells were cotransfected with 5 g of expression vectors for vIRF4 and HA-tagged CBF1 and the indicated CBF1 mutants
(EEF233AAA, KLV249AAA, F235I, K249M, adn A258V). Immunoprecipitations were performed using an HA-specific antibody. For immuno-
blotting, HA-specific and vIRF4-specific antibodies were used.
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vealing an intriguing plasticity of vIRF4 localization in re-
sponse to binding partners (37). So far, vIRF4 is not assumed
to be involved in IFN signaling. It interacts with the poly(A)
binding protein (PABP) and could potentially interfere with
host translation (15). In addition, vIRF4 stabilizes MDM2 by
preventing its autoubiquitination and thereby indirectly pro-
motes p53 degradation (25).
Although we do not provide direct structural data sets, our
results strongly indicate that complexes of vIRF4 or Notch with
CBF1 share important characteristics. The vIRF4/CBF1 inter-
action can be reconstituted in vitro and appears not to require
additional adaptor proteins. However, the Notch/CBF1 inter-
action can also be reconstituted in vitro, but it is known that the
mastermind protein is an integral component of Notch/CBF1
signaling (16). Thus, our data do not exclude the option that
additional viral or cellular proteins support the vIRF4/CBF1
interaction. In particular, in EBV and KSHV doubly infected
PEL cell lines, CBF1 might be a major hub which integrates
viral and cellular signals by direct protein-protein interactions.
Biophysical studies have shown that the WP motif flanked
by a stretch of basic amino acids within the RAM region of
Notch is the primary site of high-affinity binding of NICD to
CBF1 (14, 30). Parallel studies in yeast two-hybrid assays and
coimmunoprecipitation showed that vIRF4 interacts with
CBF1 via one high-affinity binding site consisting of not more
than 13 amino acids and a secondary low-affinity binding site of
40 amino acids. The W and P residues within the high-affinity
binding fragment are critical for the CBF1 interaction with
BTD of the 13-residue vIRF4 peptide and of the entire vIRF4
protein. However, according to the results of the very sensitive
semiquantitative yeast two-hybrid assay, a complete loss of
CBF1 binding could be achieved only by alanine substitution
for the W(471) and P(473) residues combined with the 201-to-
240 deletion. Indeed, RTA also targets CBF1 via two noncon-
secutive regions within its primary sequence (26).
In addition, our study also showed that vIRF4 cannot bind to
CBF1 mutants which carry inactivating mutations located in
the hydrophobic pocket of the BTD which prevent Notch bind-
ing. Thus, both proteins are likely to target the same region of
the hydrophobic pocket, even if the WP motif is not strictly
conserved in vIRF4, where the second  residue is occupied by
the positively charged histidine. Comparison of Notch ortho-
logues reveals that Caenorhabditis remanei and C. briggsae
Notch proteins do not obey the WP rule since they carry an
uncharged nonpolar threonine at the respective site (14). In-
deed, a closer look at the published CBF1/RAM structure
reveals that the respective hydrophobic residue is not oriented
toward the hydrophobic pocket (42). Our gel retardation as-
says show that the vIRF4 peptide can specifically interfere with
CBF1/RAM complex formation. These observations are fur-
ther supported in reporter gene assays where vIRF4 interferes
with CBF1-dependent Notch transactivation. In summary, it
appears that vIRF4 and NICD binding to CBF1 will be mutu-
ally exclusive and vIRF4 can interfere with promoter activation
by NICD via direct competition.
Both human gammaherpesviruses, Epstein-Barr virus
(EBV) and KSHV, express viral factors which interact with
CBF1, the central downstream element of Notch signaling. In
EBV latently infected B cells, the Epstein-Barr virus nuclear
antigens 2, 3A, 3B, and 3C interact with CBF1 to activate
resting B cells and establish latent infection (13). In KSHV-
infected cells, lytic cycle activation by RTA is CBF1 dependent
and activation of multiple viral RTA target genes requires
CBF1 response elements (38). In addition, LANA and RTA
interactions with CBF1 might establish an autoregulatory loop
which could stabilize the status of latency in infected cells (20).
However, CBF1 is not required for the establishment of la-
tency in KSHV-infected cells (27).
Up to now, there have been no X-ray structural data avail-
able describing CBF1 in complexes with viral proteins. How-
ever, good biochemical and biophysical evidence indicates that
EBNA-2 also targets the CBF1 BTD through a small fragment
carrying a WP motif. Such detailed analysis is not available
for RTA, LANA, or any of the EBNA-3 proteins. How vIRF4
modulates CBF1-dependent signaling in KSHV-infected cells,
FIG. 6. The vIRF4 peptide efficiently competes with RAM for
CBF1 complex formation on DNA. Complex formation of full-length
CBF1 and the Notch fragment RAM was tested in gel retardation
assays. (A) The 32P-labeled Cp oligonucleotide was incubated with 5
pmol of purified CBF1 (lane 2). *, competition was performed with
100-fold excess of the unlabeled Cp oligonucleotide (lane 3); **, a
CBF1-specific rat antibody was added to confirm CBF1/Cp complex
formation (lane 4). Forty pmol purified RAM was added (lanes 5 to
14), and complex formation was analyzed in the presence of increasing
amounts of a Notch peptide (N pept.wt; lanes 7 to 10 and 15; numbers
indicate pmol) or a mutant Notch peptide (N pept.mt; lanes 11 to 14
and 16; numbers indicate pmol). ***, as a control, GST was added to
lane 17. For the experiment shown in panel B, the Notch peptides were
replaced by vIRF4/K10 peptides (K10 pept.wt, lanes 7 to 10 and 15) or
mutant peptide (K10 pept.mt, lanes 11 to 14 and 16).
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whether it directly modulates viral and cellular gene expression
programs or rather interferes with the activity of other tran-
scription factors targeting the hydrophobic pocket of CBF1,
remains to be studied.
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